Skip to content

Kazia in pact with Dana-Farber for its lead asset in primary CNS lymphoma

September 22, 2020

Kazia Therapeutics (KZIA +0.9%) has collaborated with Dana-Farber Cancer Institute (DFCI), to investigate its lead drug, paxalisib (formerly GDC-0084), in primary central nervous system (PCNSL) lymphoma, a potential new indication for the drug.

DFCI will initiate an open-label Phase 2 trial of paxalisib in PCNSL, and expects to recruit up to 25 patients, taking up to 2 years to complete. This trial will be sixth ongoing trial of paxalisib in brain cancer.

Kazia will provide support including study drug and a financial grant.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: